← All trials
NCT07272499
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2025
- Primary completion
- Sep 10, 2028
- Completion date
- Sep 10, 2028
- First posted
- Dec 9, 2025
- Last posted
- Dec 9, 2025
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Wenzhou Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Shandong UniversityCollaborator
- Fudan UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Central South UniversityCollaborator
- Tongji UniversityCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.